Radalbuvir

Drug Profile

Radalbuvir

Alternative Names: GS-9669

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases
  • Class Amides; Antivirals; Carboxylic acids; Cyclohexanes; Cyclohexenes; Small molecules; Thiophenes
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Puerto Rico (PO, Tablet)
  • 01 Jul 2014 Gilead completes a phase II trial for Hepatitis C (in combination with ledipasvir/sofosbuvir; Treatment-naive; Treatment-experienced) in USA (NCT01984294)
  • 01 Dec 2013 Gilead Sciences completes the ELECTRON phase IIb trial in Hepatitis C (combination therapy, treatment-naive) in New Zealand (NCT01260350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top